Diagnosis and treatment of recurrent high grade glioma

doi:10.3760/cma.j.issn.1673-422X.2017.10.011

Abstract

Abstract: High grade glioma is a kind of malignant brain tumor with strong invasiveness, which progresses commonly after initial treatments and shows high mortality. Early diagnosis of tumor recurrence and highlyindividualized systemic treatment mean significance to prolong survival. Multimode magnetic resonance imaging and molecular imaging play important roles in differential diagnosis and prognosis evaluation for recurrence. Therapeutic strategies like reoperation, reirradiation, electric field technology, chemotherapy, targeted therapies and immunotherapeutic approaches are expected to bring survival benefits for patients with recurrent high grade glioma.

Key words: Glioma, Recurrence, Highgrade

Liu Xue, Ren Qinglan. Diagnosis and treatment of recurrent high grade glioma[J]. Journal of International Oncology, 2017, 44(10): 767-770.

References

［1］ Zhou X, Liao X, Zhang B, et al. Recurrence patterns in patients with highgrade glioma following temozolomidebased chemoradiotherapy［J］. Mol Clin Oncol, 2016, 5(2): 289294. DOI: 10.3892/mco.2016.936. ［2］ Virga J, Bognár L, Hortobágyi T, et al. Tumor grade versus expression of invasionrelated molecules in astrocytoma［J］. Pathol Oncol Res, 2017, In press. DOI: 10.1007/s1225301701946. ［3］ Sanghvi D. Posttreatment imaging of highgrade gliomas［J］. Indian J Radiol Imaging, 2015, 25(2): 102108. DOI: 10.4103/09713026.155829. ［4］ Fatterpekar GM, Galheigo D, Narayana A, et al. Treatmentrelated change versus tumor recurrence in highgrade gliomas: a diagnostic conundrumuse of dynamic susceptibility contrastenhanced (DSC) perfusion MRI［J］. AJR Am J Roentgenol, 2012, 198(1): 1926. DOI: 10.2214/AJR.11.7417. ［5］ Garcia JR, Cozar M, Baquero M, et al. The value of 11Cmethionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a highgrade glioma and indeterminate MRI［J］. Rev Esp Med Nucl Imagen Mol, 2017, 36(2): 8590. DOI: 10.1016/j.remn.2016.06.002. ［6］ Lucas JT Jr, Serrano N, Kim H, et al. 11CMethionine positron emission tomography delineates noncontrast enhancing tumor regions at high risk for recurrence in pediatric highgrade glioma［J］. J Neurooncol, 2017, 132(1): 163170. DOI: 10.1007/s110600162354z. ［7］ Fleischmann DF, Unterrainer M, Bartenstein P, et al. 18FFET PET prior to recurrent highgrade glioma reirradiationadditional prognostic value of dynamic timetopeak analysis and early static summation images?［J］. J Neurooncol, 2017, 132(2): 277286. DOI: 10.1007/s1106001623668. ［8］ Chen MW, Morsy AA, Liang S, et al. Redo craniotomy for recurrent grade Ⅳ glioblastomas: impact and outcomes from the national neuroscience institute singapore［J］. World Neurosurg, 2016, 87: 439445. DOI: 10.1016/j.wneu.2015.10.051. ［9］ Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of highgrade gliomas: a metaanalysis［J］. J Neurooncol, 2015, 122(2): 367382. DOI: 10.1007/s1106001517242. ［10］ Pinzi V, Orsi C, Marchetti M, et al. Radiosurgery reirradiation for highgrade glioma recurrence: a retrospective analysis［J］. Neurol Sci, 2015, 36(8): 14311440. DOI: 10.1007/s1007201521727. ［11］ Conti A, Pontoriero A, Arpa D, et al. Efficacy and toxicity of CyberKnife reirradiation and "dose dense" temozolomide for recurrent gliomas［J］. Acta Neurochir (Wien), 2012, 154(2): 203209. DOI: 10.1007/s0070101111841. ［12］ Shi W, Palmer JD, WernerWasik M, et al. Phase Ⅰ trial of panobinostat and fractionated stereotactic reirradiation therapy for recurrent high grade gliomas［J］. J Neurooncol, 2016, 127(3): 535539. DOI: 10.1007/s1106001620593. ［13］ Kleinberg LR, Stieber V, Mikkelsen T, et al. Outcome of adult brain tumor consortium (ABTC) prospective dosefinding trials of I125 balloon brachytherapy in highgrade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar［J］. J Radiat Oncol, 2015, 4(3): 235241. DOI: 10.1007/s135660150210y. ［14］ Schwartz C, Romagna A, Thon N, et al. Outcome and toxicity profile of salvage lowdoserate iodine125 stereotactic brachytherapy in recurrent highgrade gliomas［J］. Acta Neurochir (Wien), 2015, 157(10): 17571764. DOI: 10.1007/s0070101525501. ［15］ Perry JR, Bélanger K, Mason WP, et al. Phase Ⅱ trial of continuous doseintense temozolomide in recurrent malignant glioma: RESCUE study［J］. J Clin Oncol, 2010, 28(12): 20512057. DOI: 10.1200/JCO.2009.26.5520. ［16］ Egan G, Cervone KA, Philips PC, et al. Phase Ⅰ study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease［J］. Bone Marrow Transplant, 2016, 51(4): 542545. DOI: 10.1038/bmt.2015.313. ［17］ Lan F, Yang Y, Han J, et al. Sulforaphane reverses chemoresistance to temozolomide in glioblastoma cells by NFκBdependent pathway downregulating MGMT expression［J］. Int J Oncol, 2016, 48(2): 559568. DOI: 10.3892/ijo.2015.3271. ［18］ Soda Y, Marumoto T, FriedmannMorvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells［J］. Proc Natl Acad Sci USA, 2011, 108(11): 42744280. DOI: 10.1073/pnas.1016030108. ［19］ Wang Y, Xing D, Zhao M, et al. The role of a single angiogenesis inhibitor in the treatment of recurrent glioblastoma multiforme: a metaanalysis and systematic review［J］. PLoS One, 2016, 11(3): e0152170. DOI: 10.1371/journal.pone.0152170. ［20］ Lassen U, Sorensen M, Gaziel TB, et al. Phase Ⅱ study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme［J］. Anticancer Res, 2013, 33(4): 16571660. ［21］ Taal W, Oosterkamp HM, Walenkamp AM, et al. Singleagent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial［J］. Lancet Oncol, 2014, 15(9): 943953. DOI: 10.1016/S14702045(14)703146. ［22］ Zeng J, See AP, Phallen J, et al. AntiPD1 blockade and stereotactic radiation produce longterm survival in mice with intracranial gliomas［J］. Int J Radiat Oncol Biol Phys, 2013, 86(2): 343349. DOI: 10.1016/j.ijrobp.2012.12.025. ［23］ Carter T, Shaw H, CohnBrown D, et al. Ipilimumab and bevacizumab in glioblastoma［J］. Clin Oncol (R Coll Radiol), 2016, 28(10): 622626. DOI: 10.1016/j.clon.2016.04.042. ［24］ Müller K, Henke G, Pietschmann S, et al. Reirradiation or reoperation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed highgrade gliomas by means of a new prognostic model［J］. J Neurooncol, 2015, 124(2): 325332. DOI: 10.1007/s1106001518448. ［25］ Akasaki Y, Kikuchi T, Homma S, et al. Phase Ⅰ/Ⅱ trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma［J］. Cancer Immunol Immunother, 2016, 65(12): 14991509. DOI: 10.1007/s0026201619057. ［26］ Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells［J］. Sci Rep, 2015, 5: 18046. DOI: 10.1038/srep18046. ［27］ Stupp R, Wong ET, Kanner AA, et al. NovoTTF100A versus physician′s choice chemotherapy in recurrent glioblastoma: a randomised phase Ⅲ trial of a novel treatment modality［J］. Eur J Cancer, 2012, 48(14): 21922202. DOI: 10.1016/j.ejca.2012.04.011. ［28］ Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF100ATM system for glioblastoma: the patient registry dataset (PRiDe)［J］. Semin Oncol, 2014, 41 Suppl 6: S4S13. DOI: 10.1053/j.seminoncol.2014.09.010.

[1]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[3]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[4]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[5]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[6]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[7]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.
[8]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[9]	Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361.
[10]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[11]	Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607.
[12]	Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma [J]. Journal of International Oncology, 2021, 48(6): 362-365.
[13]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei. Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis [J]. Journal of International Oncology, 2021, 48(4): 193-199.
[14]	Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma [J]. Journal of International Oncology, 2021, 48(3): 172-175.
[15]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng. Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(12): 755-759.